JP7416629B2 - 免疫応答を増強するための物質および方法 - Google Patents
免疫応答を増強するための物質および方法 Download PDFInfo
- Publication number
- JP7416629B2 JP7416629B2 JP2019569301A JP2019569301A JP7416629B2 JP 7416629 B2 JP7416629 B2 JP 7416629B2 JP 2019569301 A JP2019569301 A JP 2019569301A JP 2019569301 A JP2019569301 A JP 2019569301A JP 7416629 B2 JP7416629 B2 JP 7416629B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cells
- mammal
- naive
- antigen receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 142
- 239000000126 substance Substances 0.000 title description 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 286
- 241000124008 Mammalia Species 0.000 claims description 179
- 206010028980 Neoplasm Diseases 0.000 claims description 177
- 102000006306 Antigen Receptors Human genes 0.000 claims description 153
- 108010083359 Antigen Receptors Proteins 0.000 claims description 153
- 239000000203 mixture Substances 0.000 claims description 114
- 210000004027 cell Anatomy 0.000 claims description 96
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 94
- 239000000427 antigen Substances 0.000 claims description 92
- 108091007433 antigens Proteins 0.000 claims description 92
- 102000036639 antigens Human genes 0.000 claims description 92
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 91
- 229920001184 polypeptide Polymers 0.000 claims description 90
- 150000007523 nucleic acids Chemical class 0.000 claims description 85
- 241000700605 Viruses Species 0.000 claims description 77
- 201000011510 cancer Diseases 0.000 claims description 75
- 102000039446 nucleic acids Human genes 0.000 claims description 75
- 108020004707 nucleic acids Proteins 0.000 claims description 75
- 238000001727 in vivo Methods 0.000 claims description 73
- 239000013598 vector Substances 0.000 claims description 60
- 239000013603 viral vector Substances 0.000 claims description 54
- 210000001165 lymph node Anatomy 0.000 claims description 53
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 52
- 102000043129 MHC class I family Human genes 0.000 claims description 43
- 108091054437 MHC class I family Proteins 0.000 claims description 43
- 238000002347 injection Methods 0.000 claims description 42
- 239000007924 injection Substances 0.000 claims description 42
- 241000701161 unidentified adenovirus Species 0.000 claims description 42
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 24
- 238000011065 in-situ storage Methods 0.000 claims description 20
- 230000003213 activating effect Effects 0.000 claims description 18
- 108091008874 T cell receptors Proteins 0.000 claims description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 12
- 230000001177 retroviral effect Effects 0.000 claims description 11
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 9
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims description 9
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 9
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 9
- 102000007298 Mucin-1 Human genes 0.000 claims description 9
- 108010008707 Mucin-1 Proteins 0.000 claims description 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 9
- 102000015694 estrogen receptors Human genes 0.000 claims description 9
- 108010038795 estrogen receptors Proteins 0.000 claims description 9
- 238000010253 intravenous injection Methods 0.000 claims description 9
- 238000002512 chemotherapy Methods 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 7
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims description 7
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 7
- 108010052199 HLA-C Antigens Proteins 0.000 claims description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 2
- JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 46
- 150000001413 amino acids Chemical group 0.000 description 35
- 230000004913 activation Effects 0.000 description 22
- 230000000961 alloantigen Effects 0.000 description 14
- 210000003719 b-lymphocyte Anatomy 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 241000282412 Homo Species 0.000 description 12
- 238000010361 transduction Methods 0.000 description 12
- 230000026683 transduction Effects 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 241000713666 Lentivirus Species 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 210000004988 splenocyte Anatomy 0.000 description 9
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 8
- 230000000735 allogeneic effect Effects 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 210000004989 spleen cell Anatomy 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 241001430294 unidentified retrovirus Species 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 241000709664 Picornaviridae Species 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002463 transducing effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 4
- 108010051219 Cre recombinase Proteins 0.000 description 4
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 4
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 4
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- 108010005327 CD19-specific chimeric antigen receptor Proteins 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 241000227653 Lycopersicon Species 0.000 description 3
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 210000005212 secondary lymphoid organ Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011357 CAR T-cell therapy Methods 0.000 description 2
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108010087480 HLA-B40 Antigen Proteins 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 241000701151 Human adenovirus 6 Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 229940021704 adenovirus vaccine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003699 evans blue Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 206010065305 Cancer in remission Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000010451 Folate receptor alpha Human genes 0.000 description 1
- 108050001931 Folate receptor alpha Proteins 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000603882 Homo sapiens Nuclear receptor subfamily 1 group I member 3 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700005089 MHC Class I Genes Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001581 salivary duct Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 238000001521 two-tailed test Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024000257A JP2024038256A (ja) | 2017-06-16 | 2024-01-04 | 免疫応答を増強するための物質および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521011P | 2017-06-16 | 2017-06-16 | |
| US62/521,011 | 2017-06-16 | ||
| US201862618399P | 2018-01-17 | 2018-01-17 | |
| US62/618,399 | 2018-01-17 | ||
| PCT/US2018/037874 WO2018232318A1 (en) | 2017-06-16 | 2018-06-15 | Materials and methods for increasing immune responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000257A Division JP2024038256A (ja) | 2017-06-16 | 2024-01-04 | 免疫応答を増強するための物質および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524997A JP2020524997A (ja) | 2020-08-27 |
| JP7416629B2 true JP7416629B2 (ja) | 2024-01-17 |
Family
ID=64660538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569301A Active JP7416629B2 (ja) | 2017-06-16 | 2018-06-15 | 免疫応答を増強するための物質および方法 |
| JP2024000257A Ceased JP2024038256A (ja) | 2017-06-16 | 2024-01-04 | 免疫応答を増強するための物質および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024000257A Ceased JP2024038256A (ja) | 2017-06-16 | 2024-01-04 | 免疫応答を増強するための物質および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200171170A1 (https=) |
| EP (1) | EP3638262A4 (https=) |
| JP (2) | JP7416629B2 (https=) |
| CN (1) | CN110996974A (https=) |
| AU (2) | AU2018283319B2 (https=) |
| CA (1) | CA3067226A1 (https=) |
| MX (1) | MX2019015183A (https=) |
| WO (1) | WO2018232318A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10689460B2 (en) | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| WO2024238903A1 (en) * | 2023-05-17 | 2024-11-21 | Mayo Foundation For Medical Education And Research | Materials and methods for increasing immune responses within a mammal |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004031380A1 (ja) | 2002-10-01 | 2004-04-15 | Dnavec Research Inc. | TAP活性の阻害により MHC class I による外来エピトープの提示を増強する方法 |
| US20050250161A1 (en) | 1999-06-15 | 2005-11-10 | The Trustees Of Columbia University | Generation of antigen specific T suppressor cells for treatment of rejection |
| US20080226664A1 (en) | 2001-05-04 | 2008-09-18 | Ludwig Institute For Cancer Research | Colon cancer antigen panel |
| US20120141537A1 (en) | 2010-11-18 | 2012-06-07 | Pease Larry R | Enhancing t cell activation using altered mhc-peptide ligands |
| WO2017015427A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| WO2017034615A1 (en) | 2014-08-28 | 2017-03-02 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| WO2017075389A1 (en) | 2015-10-30 | 2017-05-04 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040258688A1 (en) * | 1995-01-31 | 2004-12-23 | Daniel Hawiger | Enhanced antigen delivery and modulation of the immune response therefrom |
| US7811816B2 (en) * | 2001-05-15 | 2010-10-12 | Ortho-Mcneil Pharmaeutical, Inc. | Isolated CD8 +T lymphocytes specifically cytotoxic for a disease causing target cell |
| US20030049253A1 (en) * | 2001-08-08 | 2003-03-13 | Li Frank Q. | Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines |
| PL1897548T5 (pl) * | 2003-02-28 | 2025-03-17 | The Johns Hopkins University | Regulacja komórek T |
| US20050238626A1 (en) * | 2004-04-01 | 2005-10-27 | Lili Yang | Antigen specific T cell therapy |
| EP2494038B1 (en) * | 2009-10-27 | 2019-06-26 | Immunicum AB | Method for proliferation of antigen-specific t cells |
| US9511151B2 (en) * | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| CN107858333B (zh) | 2011-10-28 | 2022-05-27 | 瑞泽恩制药公司 | T细胞受体基因修饰小鼠 |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| EP2990416B1 (en) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| EP4286511A3 (en) * | 2015-06-12 | 2024-03-06 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| WO2018175476A1 (en) * | 2017-03-20 | 2018-09-27 | Baylor College Of Medicine | Transgenic c-mpl provides ligand-dependent co-stimulation and cytokine signals to tcr-engineered cells |
-
2018
- 2018-06-15 EP EP18817728.1A patent/EP3638262A4/en active Pending
- 2018-06-15 MX MX2019015183A patent/MX2019015183A/es unknown
- 2018-06-15 US US16/623,268 patent/US20200171170A1/en active Pending
- 2018-06-15 JP JP2019569301A patent/JP7416629B2/ja active Active
- 2018-06-15 WO PCT/US2018/037874 patent/WO2018232318A1/en not_active Ceased
- 2018-06-15 CN CN201880052389.0A patent/CN110996974A/zh active Pending
- 2018-06-15 CA CA3067226A patent/CA3067226A1/en active Pending
- 2018-06-15 AU AU2018283319A patent/AU2018283319B2/en active Active
-
2024
- 2024-01-04 JP JP2024000257A patent/JP2024038256A/ja not_active Ceased
- 2024-01-17 AU AU2024200316A patent/AU2024200316A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050250161A1 (en) | 1999-06-15 | 2005-11-10 | The Trustees Of Columbia University | Generation of antigen specific T suppressor cells for treatment of rejection |
| US20080226664A1 (en) | 2001-05-04 | 2008-09-18 | Ludwig Institute For Cancer Research | Colon cancer antigen panel |
| WO2004031380A1 (ja) | 2002-10-01 | 2004-04-15 | Dnavec Research Inc. | TAP活性の阻害により MHC class I による外来エピトープの提示を増強する方法 |
| US20120141537A1 (en) | 2010-11-18 | 2012-06-07 | Pease Larry R | Enhancing t cell activation using altered mhc-peptide ligands |
| WO2017034615A1 (en) | 2014-08-28 | 2017-03-02 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| WO2017015427A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| WO2017075389A1 (en) | 2015-10-30 | 2017-05-04 | The Regents Of The Universtiy Of California | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
Non-Patent Citations (4)
| Title |
|---|
| Immunological Reviews，1997年，Vol.156, No.1，pp.67-78 |
| J. Immunol.，2001年，Vol.166，pp.5430-5438 |
| Molecular Therapy，2016年，Vol.24, Suppl.1, No.506，p.S201 |
| PNAS，2001年，Vol.98, No.8，pp.3199-3203 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3638262A4 (en) | 2021-03-24 |
| JP2024038256A (ja) | 2024-03-19 |
| EP3638262A1 (en) | 2020-04-22 |
| AU2018283319B2 (en) | 2023-11-09 |
| WO2018232318A1 (en) | 2018-12-20 |
| AU2018283319A1 (en) | 2020-01-16 |
| CA3067226A1 (en) | 2018-12-20 |
| AU2024200316A1 (en) | 2024-02-08 |
| JP2020524997A (ja) | 2020-08-27 |
| CN110996974A (zh) | 2020-04-10 |
| US20200171170A1 (en) | 2020-06-04 |
| MX2019015183A (es) | 2020-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiao et al. | CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy | |
| JP2024009805A (ja) | 初代細胞の遺伝子編集 | |
| US20230145817A1 (en) | Neoepitope vaccine and immune stimulant combinations and methods | |
| US11965177B2 (en) | Method of manufacturing dual specific T-cells for use in cancer immunotherapy | |
| US20100292309A1 (en) | Inducing immune-mediated tumor cell death | |
| JP2024038256A (ja) | 免疫応答を増強するための物質および方法 | |
| Mierzejewska et al. | The beneficial effect of IL‐12 and IL‐18 transduced dendritic cells stimulated with tumor antigens on generation of an antitumor response in a mouse colon carcinoma model | |
| US11564980B2 (en) | Tumor treatment method with an individualized peptide vaccine | |
| US10029003B2 (en) | Methods and materials for treating cancer | |
| Saha et al. | Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen | |
| JP2021536247A (ja) | 併用療法用ｄｎａワクチンを標的とするネオアンチゲン | |
| WO2011062909A2 (en) | Creating bioengineered lymph nodes | |
| Wang et al. | Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus | |
| Schütz et al. | MHC‐Ig induces memory T cell formation in vivo and inhibits tumour growth | |
| US20250319144A1 (en) | Recombinant Armed Oncolytic Virus Composition and Use Thereof in TIL Adoptive Therapy | |
| CN111494414A (zh) | 一种用于癌症的联合免疫治疗的药物组合及其应用 | |
| Komant et al. | Oncolytic vaccinia virus as a precision cancer vaccine platform | |
| EP4713464A1 (en) | Materials and methods for increasing immune responses within a mammal | |
| Liu et al. | Combined vaccination of personalized neoantigens and shared MICB α3 antigen enhances the antitumor response by eliciting ILC1s-mediated tumor pyroptosis | |
| Moran | Characterization of dendritic cells transduced with Venezuelan equine encephalitis virus replicon particles as therapeutic cancer vaccines | |
| Haanen et al. | Long term in vivo functionality of TCR transduced T cells | |
| Azulay | T Cell Tolerance as Function of Tumor Progression | |
| Lundberg | On immunotherapy against prostate cancer | |
| Colluru | Anti-Tumor DNA vaccination: Optimizing Antigen Expression and Presentation | |
| Ramakrishna | Strategies for improved cancer virotherapy: in vivo migration and expansion of dendritic cells enhance cross-presentation of tumor antigens in virotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210511 |
|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20210825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210825 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220324 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220412 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220629 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221012 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230124 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230418 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230501 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230725 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230915 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231205 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240104 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7416629 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |